Heron Therapeutics, Inc. — Form 10-Q Summary
Business context and reporting period
Heron Therapeutics is a biotechnology company developing medicines based on approved pharmacological agents and its Biochronomer drug-delivery technology. The company had four principal candidates: SUSTOL for chemotherapy-induced nausea and vomiting (CINV), HTX-019 for CINV, HTX-011 for postoperative pain, and HTX-003 for chronic pain and opioid addiction.
This unaudited quarterly report covers the three and six months ended June 30, 2015, with comparisons to the corresponding 2014 periods. The company had no material operating revenue and remained dependent on financing to fund research, development, and commercial-readiness activities.
Financial condition and key metrics
| Metric | Three months ended June 30 | Six months ended June 30 | ||
|---|---|---|---|---|
| 2015 | 2014 | 2015 | 2014 | |
| Research and development expense | $16.2 million | $14.3 million | $30.7 million | $25.9 million |
| General and administrative expense | $6.8 million | $4.5 million | $12.7 million | $10.2 million |
| Total operating expenses | $23.0 million | $18.8 million | $43.4 million | $36.1 million |
| Net loss | $23.1 million | $19.0 million | $43.7 million | $36.5 million |
| Basic and diluted net loss per share | $0.74 | $0.78 | $1.45 | $1.52 |
Because Heron had no material product revenue, gross margin and operating margin were not meaningful. Net loss increased year over year as operating expenses grew, although loss per share declined because of a larger share base.
- Cash and cash equivalents were $171.5 million at June 30, 2015, compared with $72.7 million at December 31, 2014.
- Net cash used in operating activities was $35.5 million for the six months ended June 30, 2015, compared with $28.2 million in the prior-year period.
- Net cash used in investing activities was $0.3 million, primarily for property and equipment.
- Net cash provided by financing activities was $134.6 million, including $128.2 million of net proceeds from a June 2015 common-stock offering and $6.3 million from stock-option exercises.
- Accumulated deficit was $358.9 million at June 30, 2015.
- Current liabilities were $16.6 million, compared with $13.6 million at December 31, 2014.
- Convertible notes had a carrying value of $1.9 million and aggregate principal outstanding of $5.5 million. The notes bear interest at 6%, mature in 2021, and may be subject to holder-requested prepayment at any time.
- Operating lease obligations totaled $1.5 million, substantially due within three years.
Material changes versus the prior comparable period
- Research and development expense increased 13% in the second quarter and 18% for the six-month period, primarily because of Phase 1 and Phase 2 clinical and manufacturing costs for HTX-011 and development costs for HTX-019. These increases were partly offset by lower SUSTOL manufacturing costs after completion of its Phase 3 program in May 2015.
- General and administrative expense increased 52% in the second quarter and 24% for the six-month period, driven mainly by higher stock-based compensation and increased preparation for a potential SUSTOL commercial launch.
- Net loss increased 22% in the second quarter and 20% for the six-month period.
- Stock-based compensation expense increased to $5.7 million for the six-month period from $4.0 million. Unrecognized compensation cost was $28.4 million at June 30, 2015, expected to be recognized over a weighted-average period of 2.2 years.
- Liquidity improved substantially because of the June 2015 equity offering. The offering issued approximately 5.5 million shares and generated $128.2 million in net proceeds, but diluted existing stockholders.
- Other expense declined to $0.1 million for the quarter and $0.3 million for the six-month period, partly because of a $0.1 million gain on the sale of property and equipment.
Guidance, outlook, risks, contingencies, and unusual items
- Management stated that existing cash and working capital were expected to fund operations through 2016 under current plans, including building commercial infrastructure for a potential SUSTOL launch and continuing clinical programs.
- SUSTOL produced positive top-line results in the Phase 3 MAGIC study, with a statistically significant improvement in delayed-phase complete response versus the comparator arm. The company resubmitted its SUSTOL NDA to the FDA in July 2015. SUSTOL was not approved at the filing date.
- Management intended to file an NDA for HTX-019 under the 505(b)(2) pathway in the second half of 2016.
- Results from two Phase 2 HTX-011 trials were expected in the second half of 2015.
- Future financing may be required if the company expands development activities, acquires strategic assets, if SUSTOL is not approved, or if SUSTOL achieves less commercial success than expected. Additional equity financing could dilute stockholders.
- Key risks include FDA approval and labeling decisions, clinical-trial safety and efficacy, manufacturing and supply constraints, commercialization and market acceptance, intellectual-property protection, collaboration opportunities, and the ability to raise capital on acceptable terms.
- Clinical-site and contract-research-organization commitments may include termination penalties, but the company stated that future costs could not be estimated with certainty.
- The company reported no legal proceedings, no off-balance-sheet arrangements, and no defaults upon senior securities. It stated that its disclosure controls and procedures were effective.
- The company remained loss-making with negative operating cash flow and had no current means of generating material operating cash flows.
Important facts for investors to verify
- FDA action and labeling scope following the July 2015 SUSTOL NDA resubmission.
- Timing and results of the HTX-011 Phase 2 trials and progress toward the HTX-019 NDA filing.
- Actual cash burn relative to the stated liquidity runway through 2016.
- Potential dilution from future equity offerings, stock options, warrants, and conversion of the convertible notes; approximately 6.9 million shares were issuable under the notes at June 30, 2015.
- Commercial-launch spending, manufacturing readiness, and supply arrangements for SUSTOL.
- Whether clinical, regulatory, manufacturing, or intellectual-property risks alter development timelines or capital requirements.